Guangxiu Dai

917 total citations
22 papers, 737 citations indexed

About

Guangxiu Dai is a scholar working on Organic Chemistry, Molecular Biology and Immunology. According to data from OpenAlex, Guangxiu Dai has authored 22 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Organic Chemistry, 6 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Guangxiu Dai's work include Catalytic C–H Functionalization Methods (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Catalytic Cross-Coupling Reactions (3 papers). Guangxiu Dai is often cited by papers focused on Catalytic C–H Functionalization Methods (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Catalytic Cross-Coupling Reactions (3 papers). Guangxiu Dai collaborates with scholars based in China and United States. Guangxiu Dai's co-authors include Richard C. Larock, Marino A. Campo, Qinhua Huang, Alessia Fazio, Weiguo Su, Weiguo Qing, Yi Gu, Yongxin Ren, Feng Zhou and Yumin Cui and has published in prestigious journals such as Journal of the American Chemical Society, Blood and Cancer Research.

In The Last Decade

Guangxiu Dai

22 papers receiving 732 citations

Peers

Countries citing papers authored by Guangxiu Dai

Since Specialization

Citations

This map shows the geographic impact of Guangxiu Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangxiu Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangxiu Dai more than expected).

Fields of papers citing papers by Guangxiu Dai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangxiu Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangxiu Dai. The network helps show where Guangxiu Dai may publish in the future.

Co-authorship network of co-authors of Guangxiu Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Guangxiu Dai. A scholar is included among the top collaborators of Guangxiu Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangxiu Dai. Guangxiu Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment 2025 ·ACS Medicinal Chemistry Letters ·(unknown), Zheng Zhang, Yao Wu, Gang Li, Jia Chen, Yongxin Ren, (unknown), Jinghong Zhou, Wei Zhang, Jian Wang, Zeyu Zhong, (unknown), (unknown), (unknown), Wenji Li, (unknown), Weihan Zhang, Weiguo Su, Guangxiu Dai	2
2	Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies 2024 ·Frontiers in Pharmacology ·Shuwen Jiang, Xiangkun Li, (unknown), (unknown), Jian Wang, (unknown), Guangxiu Dai, Weiguo Su	1
3	Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers 2024 ·ACS Medicinal Chemistry Letters ·(unknown), Wei Deng, (unknown), Min Cai, Dong Guo, (unknown), Xiaoming Dai, Zhipeng Wu, Weigang He, Jian Wang, (unknown), (unknown), Na Li, Weiguo Su, Guangxiu Dai	1
4	Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor 2023 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), (unknown), Zhipeng Wu, Weigang He, Xiaoming Dai, (unknown), Min Cheng, Na Yang, Yongxin Ren, Guanglin Wang, Jian Wang, Yang Sai, (unknown), Guangxiu Dai, (unknown), Weiguo Su	4
5	Abstract 4020: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies 2023 ·Cancer Research ·Linfang Wang, (unknown), (unknown), Jia Hu, (unknown), Xian‐Wen Yang, Fangfang Mao, Wei Zhang, Ying Yu, Qihang Zhang, Na Yang, Chun Zhang, Jian Wang, (unknown), Xiong Li, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, Weiguo Su	1
6	Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor 2020 ·Pharmacology Research & Perspectives ·Yu Cai, Jun Yu, Ping Ren, (unknown), Zhipeng Wu, Kun Xiao, Hong Peng Jia, Jian Wang, Yang Sai, Guangxiu Dai, Li Xiong, Wei-guo Su, Karen Ngo, Glenda Castro, Paul D. Acton, Wai‐Ping Fung‐Leung, James P. Edwards, (unknown), Tadimeti S. Rao	4
7	Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas 2018 ·Blood ·Jun Zhu, Junning Cao, Lugui Qiu, Junyuan Qi, Yuqin Song, Meifeng Tu, Dongmei Ji, (unknown), Mingyuan Sun, Hua Ye, Yang Chen, Yù Chen, Jian Wang, Guangxiu Dai, Weiguo Su	1
8	HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo 2016 ·Blood ·Yang Na, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, (unknown), Ying Yu, (unknown), Feng Zhou, Guangxiu Dai, Weiguo Qing, Wei-guo Su, Yongxin Ren	1
9	Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer 2014 ·Journal of Medicinal Chemistry ·(unknown), Guangxiu Dai, (unknown), (unknown), Qing Wang, Feng Zhou, (unknown), Yumin Cui, Yongxin Ren, Shiming Fan, Jinghong Zhou, Weiguo Qing, Yi Gu, Jian Wang, Yang Sai, Weiguo Su	111
10	Abstract 3371: Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor . 2013 ·Cancer Research ·Yi Gu, Yang Sai, Jian Wang, (unknown), (unknown), Yuansheng Zhao, Zhang Li, Wenqing Yang, Guangxiu Dai, Weihan Zhang, (unknown), (unknown), Weiguo Su	4
11	Abstract 971: Synergistic effect of c-Met inhibitor volitinib in combination with EGFR inhibitor Gefitnib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification. 2013 ·Cancer Research ·Feng Zhou, Yongxin Ren, Yumin Cui, Hanyang Chen, (unknown), Guangxiu Dai, Shiming Fan, (unknown), (unknown), Yang Sai, Yi Gu, Weiguo Qing, Weiguo Su	4
12	Experimental Study on Toxicity and Efficacy of Genkwa Flos stir-baked with Vinegar 2012 ·Zhonghua zhongyiyao xuekan ·Guangxiu Dai	3
13	Bifunctional inhibition of HIV-1 reverse transcriptase: A first step in designing a bifunctional triphosphate 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Aravind Basavapathruni, (unknown), Guangxiu Dai, Wolfgang Hinz, Adrian S. Ray, Eisuke Murakami, Joy Y. Feng, Fei You, Ginger E. Dutschman, David J. Austin, Kathlyn A. Parker, Karen S. Anderson	6
14	Pd-Catalyzed Alkyl to Aryl Migration and Cyclization: An Efficient Synthesis of Fused Polycycles via Multiple C−H Activation 2004 ·Journal of the American Chemical Society ·Qinhua Huang, Alessia Fazio, Guangxiu Dai, Marino A. Campo, Richard C. Larock	221
15	Synthesis of 3,4-Disubstituted Isoquinolines via Palladium-Catalyzed Cross-Coupling of 2-(1-Alkynyl)benzaldimines and Organic Halides 2003 ·The Journal of Organic Chemistry ·Guangxiu Dai, Richard C. Larock	117
16	Synthesis of 3-Substituted 4-Aroylisoquinolines via Pd-Catalyzed Carbonylative Cyclization of 2-(1-Alkynyl)benzaldimines 2002 ·The Journal of Organic Chemistry ·Guangxiu Dai, Richard C. Larock	97
17	Synthesis of 3,4-Disubstituted Isoquinolines via Palladium-Catalyzed Cross-Coupling of o-(1-Alkynyl)benzaldimines and Organic Halides 2001 ·Organic Letters ·Guangxiu Dai, Richard C. Larock	94
18	Synthesis of 3-Substituted 4-Aroylisoquinolines via Pd-Catalyzed Carbonylative Cyclization of o-(1-Alkynyl)benzaldimines 2001 ·Organic Letters ·Guangxiu Dai, Richard C. Larock	48
19	SYNTHESIS OF NOVEL DERIVATIVES OF 2-CYANO-3-METHYLTHIO-3′-BENZYLAMINO ACRYLATES(ACRYLAMIDES) AND THEIR BIOLOGICAL ACTIVITY 1999 ·Phosphorus, sulfur, and silicon and the related elements ·(unknown), Yinlin Sha, Guangxiu Dai, (unknown), Huazheng Yang, Luhua Lai	7
20	Synthesis of N-Aryl-4-ubstituted-phenyl Carbamates and Their Herbicidal Activity 1997 ·Chinese Journal of Applied Chemistry ·(unknown), Guangxiu Dai, (unknown), Xiufeng Yang, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact